Medpace Faces Securities Class Action Lawsuits
Analysis based on 40 articles · First reported Apr 07, 2026 · Last updated May 08, 2026
The class action lawsuits against Medpace by Rosen Law Firm and The Schall Law Firm could lead to significant financial liabilities for Medpace, potentially impacting its stock price and investor confidence. Investors who purchased Medpace stock during the Class Period may be entitled to compensation, which could result in a transfer of wealth from Medpace to its shareholders.
Medpace, a publicly traded company, is facing multiple class action lawsuits filed by Rosen Law Firm and The Schall Law Firm. These lawsuits allege that Medpace made false and misleading statements to the market between April 22, 2025, and February 9, 2026, concerning its backlog cancellation rates. Specifically, Medpace is accused of continuously touting 'well behaved' cancellation rates and providing overly positive growth expectations that could not maintain a projected 1.15 book-to-bill ratio. Investors who purchased Medpace securities during this period are encouraged to join the lawsuits, with lead plaintiff deadlines set for June 5, 2026 (The Schall Law Firm) and June 8, 2026 (Rosen Law Firm). Attorneys Philip Kim and Lawrence Rosen from Rosen Law Firm, and Brian Schall from The Schall Law Firm, are actively involved in these efforts to recover damages for affected shareholders.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard